Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)

This study has been completed.
Sponsor:
Collaborators:
Carmel Medical Center
Technion, Israel Institute of Technology
Information provided by (Responsible Party):
Irina Kessel, Carmel Medical Center
ClinicalTrials.gov Identifier:
NCT00800449
First received: November 30, 2008
Last updated: February 13, 2012
Last verified: February 2012
  Purpose

The Haptoglobin (Hp) gene locus at chromosome 16q22 is polymorphic with two alleles denoted 1 and 2 .The gene product exists in three phenotypes: 1-1, 2-1, and 2-2.

The Haptoglobin 2 allele is found only in man and is believed to have arisen from the Haptoglobin 1 allele by a partial intragenic duplication. Haptoglobin 2 allele frequency is higher than the Haptoglobin 1 allele. It has been hypothesized that the Haptoglobin 2 allele was spread in man due to its selective advantage against life-threatening infections.

In vitro, only the Haptoglobin 2 allele protein, binds to the streptococcus T antigen, resulting in its aggregation and slowing its growth .

Individuals homozygous for the Haptoglobin 1 allele (1-1 genotype) are more prone to the streptococcal infection than individuals with the Haptoglobin 2 allele(2-1 or 2-2 genotype).

The investigators wish to explore the linkage between Hp phenotype and sepsis in pre-term neonates, considering that in this early stage in life, genetic properties which provide a defense against infectious agents will be of heightened importance.


Condition
Neonatal Sepsis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)

Resource links provided by NLM:


Further study details as provided by Carmel Medical Center:

Biospecimen Retention:   Samples Without DNA

Hp phenotype in blood test.


Enrollment: 133
Study Start Date: August 2007
Study Completion Date: September 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   24 Weeks to 35 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All preterm neonates ( a total of 150 preterm babies, 35 weeks or younger) admitted to the NICU in Carmel hospital.

Criteria

Inclusion Criteria:

  • Preterm babies born at 35 week gestational age and younger being admitted to the preterm unit in Carmel Medical Center over a period of one year.

Exclusion Criteria:

  • Pre-term neonates with serious congenital defects.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00800449

Locations
Israel
Carmel Medical Center
Haifa, Israel, 34362
Sponsors and Collaborators
Irina Kessel
Carmel Medical Center
Technion, Israel Institute of Technology
Investigators
Principal Investigator: Irena Kessel, MD Carmel Medical Center
  More Information

No publications provided

Responsible Party: Irina Kessel, MD, Carmel Medical Center
ClinicalTrials.gov Identifier: NCT00800449     History of Changes
Other Study ID Numbers: PTSH001
Study First Received: November 30, 2008
Last Updated: February 13, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Carmel Medical Center:
Haptoglobin
sepsis
premature babies

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014